Geneos Wealth Management’s BioLineRX BLRX Stock Holding History

Geneos Wealth Management’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-120	Closed	-$1.01K	–	3081
2024 Q4	$1.01K	Buy	120 +7	+6%	+$103	﹤0.01%	2766
2024 Q3	$2.43K	Sell	113 -850	-88%	-$23.4K	﹤0.01%	2255
2024 Q2	$21.9K	Hold	963	–	–	﹤0.01%	1315
2024 Q1	$43.1K	Sell	963 -50	-5%	-$2.51K	﹤0.01%	1118
2023 Q4	$63.6K	Hold	1,013	–	–	﹤0.01%	989
2023 Q3	$73.7K	Buy	1,013 +425	+72%	+$28.6K	﹤0.01%	965
2023 Q2	$37.6K	Hold	588	–	–	﹤0.01%	1167
2023 Q1	$20.9K	Hold	588	–	–	﹤0.01%	1334
2022 Q4	$13.9K	Hold	588	–	–	﹤0.01%	1442
2022 Q3	$21K	Sell	588 -448	-43%	-$25.6K	﹤0.01%	1303
2022 Q2	$53K	Buy	1,036 +212	+26%	+$11.8K	﹤0.01%	1255
2022 Q1	$56K	Buy	824 +100	+14%	+$6.96K	﹤0.01%	1329
2021 Q4	$59K	Buy	724 +280	+63%	+$29.2K	﹤0.01%	1400
2021 Q3	$49K	Buy	444 +8	+2%	+$949	﹤0.01%	1501
2021 Q2	$58K	Buy	+436	New	+$51.3K	﹤0.01%	1403

Other funds holding BLRX

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

NRG

Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geneos Wealth Management's BLRX Position: Q1 2025 in Review

Geneos Wealth Management sold out of BioLineRX (BLRX) in Q1 2025, closing a stake of 120 shares — an estimated $1.01K sold.

Geneos Wealth Management first reported a position in BLRX in Q2 2021 and held it in 15 quarters. The position peaked at $73.7K in Q3 2023. 12 funds tracked by Wall St. Rank hold BLRX as of Q1 2025.

Geneos Wealth Management reported no remaining BioLineRX position as of Q1 2025 after selling out during the quarter.
Geneos Wealth Management sold 120 BioLineRX shares in Q1 2025, an estimated $1.01K.
Geneos Wealth Management first reported a position in BioLineRX in Q2 2021 and held it in 15 quarters.
Geneos Wealth Management's BioLineRX position peaked at $73.7K in Q3 2023.
12 funds tracked by Wall St. Rank held BioLineRX as of Q1 2025.

Based on Geneos Wealth Management's 13F filing for Q1 2025, filed 8 May 2025.